Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Sep;32(9):1300–1303. doi: 10.1128/aac.32.9.1300

Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome.

B L Moskovitz 1
PMCID: PMC175855  PMID: 3058016

Abstract

An open-label, multicenter clinical trial assessed the tolerance of HPA-23 (ammonium-21-tungsto-9-antimoniate) in patients with acquired immune deficiency syndrome. Sixty-nine patients were sequentially assigned to receive 0.25, 0.5, 1.0, or 2.0 mg of HPA-23 per kg intravenously 5 days per week for 8 weeks. HPA-23 was fairly well tolerated at doses of 1.0 mg/kg or less; nearly 60% of patients given 2.0 mg/kg discontinued treatment. Twenty-six patients discontinued treatment because of adverse events or concurrent illness. HPA-23 produced dose-related decreases in platelet count and increases in serum glutamine oxalacetic transaminase. There were no changes in immune system function, as determined by total lymphocyte count, T4-cell count, T8-cell count, and T4/T8 ratio. The effects of HPA-23 seemed to be more closely related to the total dose than to the daily dose. No improvement in the clinical status of the patients was observed during the 8 weeks of treatment.

Full text

PDF
1300

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ablashi D. V., Twardzik D. R., Easton J. M., Armstrong G. R., Luetzeler J., Jasmin C., Chermann J. C. Effects of 5-tungsto-2-antimoniate in oncogenic DNA and RNA virus-cell systems. Eur J Cancer. 1977 Jul;13(7):713–720. doi: 10.1016/0014-2964(77)90058-5. [DOI] [PubMed] [Google Scholar]
  2. Barré-Sinoussi F., Chermann J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vézinet-Brun F., Rouzioux C. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868–871. doi: 10.1126/science.6189183. [DOI] [PubMed] [Google Scholar]
  3. Buimovici-Klein E., Ong K. R., Lange M., Englard A., McKinley G. F., Reddy M., Grieco M. H., Cooper L. Z. Reverse transcriptase activity (RTA) in lymphocyte cultures of AIDS patients treated with HPA-23. AIDS Res. 1986 Fall;2(4):279–283. doi: 10.1089/aid.1.1986.2.279. [DOI] [PubMed] [Google Scholar]
  4. Chermann J. C., Sinoussi F. C., Jasmin C. Inhibition of RNA-dependent DNA polymerase of murine oncornaviruses by ammonium-5-tungsto-2-antimoniate. Biochem Biophys Res Commun. 1975 Aug 18;65(4):1229–1236. doi: 10.1016/s0006-291x(75)80361-5. [DOI] [PubMed] [Google Scholar]
  5. Gallo R. C., Salahuddin S. Z., Popovic M., Shearer G. M., Kaplan M., Haynes B. F., Palker T. J., Redfield R., Oleske J., Safai B. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984 May 4;224(4648):500–503. doi: 10.1126/science.6200936. [DOI] [PubMed] [Google Scholar]
  6. Herve M., Sinoussi-Barre F., Chermann J. C., Herve G., Jasmin C. Correlation between structure of polyoxotungstates and their inhibitory activity on polymerases. Biochem Biophys Res Commun. 1983 Oct 14;116(1):222–229. doi: 10.1016/0006-291x(83)90404-7. [DOI] [PubMed] [Google Scholar]
  7. Kimberlin R. H., Walker C. A. The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch Virol. 1983;78(1-2):9–18. doi: 10.1007/BF01310854. [DOI] [PubMed] [Google Scholar]
  8. Ono K., Nakane H., Matsumoto T., Barré-Sinoussi F., Chermann J. C. Inhibition of DNA polymerase alpha activity by ammonium 21-tungsto-9-antimoniate (HPA23). Nucleic Acids Symp Ser. 1984;(15):169–172. [PubMed] [Google Scholar]
  9. Popovic M., Sarngadharan M. G., Read E., Gallo R. C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984 May 4;224(4648):497–500. doi: 10.1126/science.6200935. [DOI] [PubMed] [Google Scholar]
  10. Rozenbaum W., Dormont D., Spire B., Vilmer E., Gentilini M., Griscelli C., Montagnier L., Barre-Sinoussi F., Chermann J. C. Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome. Lancet. 1985 Feb 23;1(8426):450–451. doi: 10.1016/s0140-6736(85)91162-6. [DOI] [PubMed] [Google Scholar]
  11. Sarngadharan M. G., Popovic M., Bruch L., Schüpbach J., Gallo R. C. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science. 1984 May 4;224(4648):506–508. doi: 10.1126/science.6324345. [DOI] [PubMed] [Google Scholar]
  12. Souyri-Caporale M., Tovey M. G., Ono K., Jasmin C., Chermann J. C. Modulation by the polyoxotungstate HPA-23 of Epstein-Barr virus early antigen expression in Raji cells treated with iododeoxyuridine. J Gen Virol. 1984 Apr;65(Pt 4):831–835. doi: 10.1099/0022-1317-65-4-831. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES